Company News

Alexion Pharmaceuticals and Procter & Gamble Complete Enrollment in Cardiac Bypass Surgery Trial

Author Image

By: TOM BRANNA

Editor

Alexion Pharmaceuticals, Inc. and Procter & Gamble Pharmaceuticals (P&GP), have announced the completion of enrollment for the pivotal Phase III PRIMO-CABG2 efficacy trial of pexelizumab. This product is being investigated for reducing mortality and heart attacks following coronary artery bypass graft (CABG) surgery. The Pexelizumab for Reduction of Infarction and Mortality in Coronary Artery Bypass Graft surgery 2 (PRIMO-CABG2) pivotal Phase III trial is examining the effect of pex...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters